Background: Myeloproliferative neoplasms (MPNs) are clonal-origin hematopoietic stem cell disorders. Molecular studies in case of BCR-ABL negative MPN (JAK2v617F, CALR and MPL) have revolutionised the diagnostic approach of MPNs. PV is expected to be almost always accompanied by a JAK2 mutation, whereas the specific driver mutation cannot otherwise distinguish one MPN from another; however, in distinguishing ET from pre -PMF or PV, a higher JAK2V617F allele burden favours the diagnosis of the latter rather than the former. Method: This was a cross – sectional study, for 18 months from from 1st November 2019 to 30th May2021 including review of clinical presentation, peripheral blood, BMA, and BMB along with clinical features in cases with BCR- ABLand JAK2V617F CALR and MPL mutation analysis.